Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

3.715 +0.045 (+1.23%)
Streaming Delayed Price Updated: 10:29 AM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 Next >
News headline image
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Provides 2025 Corporate and Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
From Whitefort Capital Management, LP
Via Business Wire
News headline image
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Participate in Jefferies Global Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present Imdusiran Data at EASL Congress 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
From Whitefort Capital Management, LP
Via Business Wire
News headline image
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.